Ideaya Biosciences Inc.

6 trials 2 recruiting Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

2 Completed trials

10 Countries active

11 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase I/II

Phase I

Phase III: 1 Phase II/III: 2 Phase II: 1 Phase I/II: 1 Phase I: 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Uveal melanoma 4

Top IMPs

DAROVASERTIB 4 DURVALUMAB 1 IDE-161 1 IDE849 1

All trials

6 total

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE META… Not authorised

2023-506686-66-00 Phase II/III 1 country DAROVASERTIB
Study with IDE849 for patients with DLL3 positive cancer, including small cell lung cancer Pending

2025-523438-24-00 Phase I/II 2 countries DURVALUMAB; IDE-161; IDE849
Darovasertib before Surgery or Radiation Therapy to Treat Early-stage Eye Cancer (Uveal Melanoma) Recruiting

2025-522387-32-00 Phase III 10 countries DAROVASERTIB
IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting

2023-506686-66-01 Phase II/III 7 countries DAROVASERTIB
(Treatments to shrink tumors before surgery, radiation or other forms of nondrug therapy) to use the investigational drug (Darovasertib) in … Ended

2023-506683-14-00 Phase II 4 countries DAROVASERTIB
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult P… Ended

2024-510995-18-00 Phase I 3 countries

Showing 1–6 of 6 trials

← All sponsors A–Z